Lymphadenectomy in Early Ovarian Cancer

Ovarian Cancer Clinical Trial

— LOVE  

Official title:

A Prospective Randomized Multicentre Trial for Lymphadenectomy in Early-stage Ovarian Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04710797
• Other study ID #: 2020-FXY-405
• Status: Recruiting
• Phase: N/A
• Start date: January 31, 2021
• Est. completion date: December 31, 2028

Study information

• Verified date: January 2021
• Source: Sun Yat-sen University
• Contact: Jihong Liu, Ph.D.
• Phone: 86-20-87343102
• Email: liujih[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the impact of comprehensive staging surgery with no lymphadenectomy on survival and quality of life in patients with early-stage ovarian cancer.

Description:

OBJECTIVES: Compare the efficacy and safety in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IA -IIA epithelial ovarian cancer, undergo completion staging surgery including systematic pelvic and para-aortic lymphadenectomy versus comprehensive staging surgery without lymphadenectomy. OUTLINE: This is a randomized phase III multicenter study. Patients will receive comprehensive staging surgery without Lymphadenectomy or completion staging surgery including systematic pelvic and para-aortic lymphadenectomy, and the adjuvant chemotherapy will accord to National Comprehensive Cancer Network (NCCN) guidelines. Patients are followed up every 3 months within the first 2 years, and then every 6 months. PROJECTED ACCRUAL: A total of 656 patients will be recruited for this study within 5 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 656
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Women aged 18 years to 70 years.

2. Primary diagnosis of epithelial ovarian cancer FIGO stage IA-IIA ( recevive no prior treatment or receive incomplete initial surgery),with indications of adjuvant chemotherapy:?High-grade serous carcinoma; ?Grade 3 endometrioid carcinoma; ?Clear cell carcinoma; ?Grade 2 endometrioid carcinoma with capsule ruptured or pelvic tissues extension ?Low-grade serous carcinoma?Grade 1 endometrioid carcinoma and Mucinous carcinoma of the ovary with pelvic tissues extension.

3. Patients who have given their signed and written informed consent.

4. Good performance status (ECOG 0/1).

Exclusion Criteria:

1. Non epithelial ovarian malignancies and borderline tumors.

2. Suspicious lymph nodes at preoperative radiological evaluation.

3. Intraoperative clinically suspicious lymph nodes (bulky nodes).

4. Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity.

5. Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy.

6. Diseases of the lymph system (including lymph edema of unknown origin).

7. Prior retroperitoneal lymph node dissection (systematic or sampling).

8. Any other concurrent medical conditions contraindicating surgery.

9. Pregnancy.

10. Any reasons interfering with giving of informed consent , abiding by protocol, or regular follow-up.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Lymphadenectomy
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Procedure:
• Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
open or minimally invasive surgical approach cytologic examinations All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied BSO and hysterectomy For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered Omentectomy Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve
• Comprehensive staging surgery with no Lymphadenectomy
open or minimally invasive surgical approach cytologic examinations All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied BSO and hysterectomy For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered Omentectomy In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes

Locations

Country	Name	City	State
China	Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS(Progression-free survival)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Secondary	OS(Overall Survival)	From date of randomization until the date of death from any cause or date of last follow up, whichever came first	From date of randomization until the date of death from any cause or date of last follow up, up to 100 mons
Secondary	Recurrence rate of lymph node	The recurrence rate in the retroperitoneal lymph nodes after primary surgery	3 years
Secondary	QoL(Quality of life)	Quality of life before surgery, and at 6 months and 1 year after surgery in both groups will be evaluated using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire	Baseline, 6 months and 1 year after surgery
Secondary	Postoperative complications	The difference of the rate of Postoperative complications between two groups	3 years